Pancreatic Cancer Research

ResearcherChristian-Albrechts-Universität zu KielActive in the last 2 years

Anna Trauzold

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4697-556X; OpenAlex author ID A5065071742. Sources: OpenAlex.

Their work

Papers
21 (first author 3, last author 6)
Trials
0
Grants
0
Labs led
1
Collaborators
70
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 1 paper · 2014: 1 paper · 2015: 1 paper · 2016: 1 paper · 2017: 2 papers · 2018: 4 papers · 2019: 2 papers · 2020: 1 paper · 2021: 2 papers · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: 1 paper · 2026: 2 papers

Papers 21

  1. Oncogenic KRAS-driven type I interferon signalling primes pancreatic cancer for necroptosis. Co-author DOI 10.1038/s41467-026-73189-8↗
  2. pH-Dependent Microenvironmental Ionic Signaling in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1111/apha.70183↗
  3. Transmembrane Protease Serine 11B Modulates Lactate Transport Through SLC16A1 in Pancreatic Ductal Adenocarcinoma-A Functional Link to Phenotype Heterogeneity. Co-author DOI 10.3390/ijms26115398↗
  4. Monocarboxylate Transporter-1 (MCT1)-Mediated Lactate Uptake Protects Pancreatic Adenocarcinoma Cells from Oxidative Stress during Glutamine Scarcity Thereby P… Co-author DOI 10.3390/antiox12101818↗
  5. Impact of Extracellular pH on Apoptotic and Non-Apoptotic TRAIL-Induced Signaling in Pancreatic Ductal Adenocarcinoma Cells. First author DOI 10.3389/fcell.2022.768579↗
  6. Prognostic significance of high mobility group A2 (HMGA2) in pancreatic ductal adenocarcinoma: malignant functions of cytoplasmic HMGA2 expression. Last author DOI 10.1007/s00432-021-03745-w↗
  7. Topology impacts TRAIL therapy: Differences in primary cancer growth and liver metastasis between orthotopic and subcutaneous xenotransplants of pancreatic duc… First author DOI 10.1016/j.hbpd.2021.04.005↗
  8. The A818-6 system as an in-vitro model for studying the role of the transportome in pancreatic cancer. Last author DOI 10.1186/s12885-020-06773-w↗
  9. The expression of death receptor systems TRAIL-R1/-R2/-R4, CD95 and TNF-R1 and their cognate ligands in pancreatic ductal adenocarcinoma. Co-author DOI 10.14670/hh-18-054↗
  10. The Hepatic Microenvironment and TRAIL-R2 Impact Outgrowth of Liver Metastases in Pancreatic Cancer after Surgical Resection. Co-author DOI 10.3390/cancers11060745↗
  11. The novel TRAIL-receptor agonist APG350 exerts superior therapeutic activity in pancreatic cancer cells. Last author DOI 10.1038/s41419-018-0478-0↗
  12. Cytoplasmic TRAIL-R1 is a positive prognostic marker in PDAC. Last author DOI 10.1186/s12885-018-4688-8↗
  13. Should We Keep Walking along the Trail for Pancreatic Cancer Treatment? Revisiting TNF-Related Apoptosis-Inducing Ligand for Anticancer Therapy. Co-author DOI 10.3390/cancers10030077↗
  14. Downregulation of TRAIL-Receptor 1 Increases TGFβ Type II Receptor Expression and TGFβ Signalling Via MicroRNA-370-3p in Pancreatic Cancer Cells. Last author DOI 10.3390/cancers10110399↗
  15. Tumor-reducing effect of the clinically used drug clofazimine in a SCID mouse model of pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.11299↗
  16. The prognostic relevance of primary tumor location in patients undergoing resection for pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.14768↗
  17. In silico analysis of the transportome in human pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00249-016-1171-9↗
  18. Proapoptotic and antiapoptotic proteins of the Bcl-2 family regulate sensitivity of pancreatic cancer cells toward gemcitabine and T-cell-mediated cytotoxicity. Co-author DOI 10.1097/cji.0000000000000073↗
  19. c-Rel is a critical mediator of NF-κB-dependent TRAIL resistance of pancreatic cancer cells. Co-author DOI 10.1038/cddis.2014.417↗
  20. TRAIL-induced expression of uPA and IL-8 strongly enhanced by overexpression of TRAF2 and Bcl-xL in pancreatic ductal adenocarcinoma cells. Last author DOI 10.1016/s1499-3872(13)60012-0↗
  21. Impact of death receptor signaling on the malignancy of pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.ejcb.2010.10.008↗

Closest collaborators

The 25 strongest of 70 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Holger Kalthoff · 11 shared papers, 2011–2021 · strength 0.95
  2. Christian Röder · 8 shared papers, 2011–2023 · strength 0.84
  3. Christoph Röcken · 5 shared papers, 2018–2025 · strength 0.65
  4. Susanne Sebens · 5 shared papers, 2014–2025 · strength 0.65
  5. Sofie Hagelund · 2 shared papers, 2022–2026 · strength 0.52
  6. H. Schäfer · 3 shared papers, 2014–2025 · strength 0.50
  7. Claudia Geismann · 3 shared papers, 2014–2025 · strength 0.50
  8. Albrecht Schwab · 2 shared papers, 2020–2026 · strength 0.31
  9. Silvia von Karstedt · 2 shared papers, 2018–2026 · strength 0.29
  10. Jan-Paul Gundlach · 3 shared papers, 2018–2021 · strength 0.29
  11. Dinara M. Baiskhanova · 1 shared paper, 2025 · strength 0.27
  12. Ivana Novak · 2 shared papers, 2016–2026 · strength 0.25
  13. Ildikò Szabó · 2 shared papers, 2017–2026 · strength 0.25
  14. Alexander Quaas · 1 shared paper, 2026 · strength 0.20
  15. Moritz Reese · 1 shared paper, 2026 · strength 0.20
  16. Sofya Tishina · 1 shared paper, 2026 · strength 0.20
  17. Maximilian Reichert · 1 shared paper, 2026 · strength 0.20
  18. Janine Murr · 1 shared paper, 2026 · strength 0.20
  19. Igor A. Astsaturov · 1 shared paper, 2026 · strength 0.20
  20. Nourhane Ammar · 1 shared paper, 2023 · strength 0.19
  21. Pawel Swietach · 1 shared paper, 2026 · strength 0.19
  22. Verena Hofschröer · 1 shared paper, 2026 · strength 0.19
  23. Laura Mezzanotte · 1 shared paper, 2026 · strength 0.19
  24. Zoltán Pethő · 1 shared paper, 2026 · strength 0.19
  25. Tiago M. A. Carvalho · 1 shared paper, 2026 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.